Rexahn Pharmaceuticals
Rexahn’s goal is to be a world-class biopharmaceutical company developing and delivering novel cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Leveraging a powerful, multi-faceted discovery engine consisting of small signaling molecule discovery, computational modeling and nanotechnology-based drug targeting and delivery, we believe that we are well on our way to achieving our goal.
Rexahn Pharma secures Japanese patent for anti-cancer drug Archexin
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN) has been issued a Japanese patent for its novel anti-cancer compound Archexin, which is currently undergoing Phase II clinical trial for the treatment of pancreatic cancer.
Patient enrolment continues at multiple sites in the US and abroad as part of the ongoing trial with preliminary results expected in the fourth quarter of 2010.
“The Japanese patent award is another step forward in the development of one of our lead clinical drug candidates, Archexin...in addition to strengthening our intellectual property portfolio, we are pleased with the progress of Archexin’s ongoing Phase II clinical trial,” said chairman and chief executive Chang Ahn.
Archexin is a potent inhibitor of Akt protein kinase in the treatment of cancer. The drug is being developed to treat solid tumors and has US FDA Orphan Drug designation for RCC, pancreatic, stomach, glioblastoma, and ovarian cancers.
Rexahn currently has three drug candidates in Phase II clinical trials, Archexin, Serdaxin and Zoraxel, which the company said were all potentially best in class therapeutics, and a pipeline of preclinical compounds to treat multiple cancers and CNS (central nervous system) disorders.
Serdaxin, which is used for the treatment of depression and Parkinson’s disease, and Zoraxel, which treats sexual dysfunction, are the company’s most advanced drugs, currently approaching the conclusion of their respective Phase II trials. The company states that its drugs have the potential to “change the paradigm of how some cancers and CNS disorders are treated, not only providing patients with new cures, but also hope for a better quality of life,” with its Phase II drugs targeting diseases where “meaningful cures” are overdue.
The preclinical compounds include RX-3117, jointly developed with Teva Pharmaceutical Industries for the treatment of cancer cells and tumors focusing on lung cancer, RX-1792 that suppresses protein kinase Akt and c-Fos, critical components of tumor growth and metastasis, RX-8243, whose trials have shown that it blocks tumor growth in xenograft models at low nanomolar concentrations and RX-0047, a potent inhibitor for HIF-1α, a key transcription factor involved in cancer cell survival, metastasis, and angiogenesis.
Rexahn also operates R&D (research and development) programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms.
The company pursues a strategy of establishing partnerships with pharmaceutical companies to develop and commercialise its drug candidates, aiming to retain significant co-promotion or co-commercialization rights in certain worldwide markets to capture long-term value from its innovations.
The company is also developing HPMA-gemcitabine and HPMA-docetaxel, anticancer drugs that can overcome the downside of cytotoxic compounds, such as poor solubility, stability, and severe adverse reactions.
Shares in Rexahn have performed very well over the past three months with the stock value more than doubling from US$0.6 to the current US$1.35 per share.
Register here to be notified of future Rexahn Pharmaceuticals articles.
Other Rexahn Pharmaceuticals articles
-
29/03/10 Rexahn Pharmaceuticals discovery platform continues to churn out potential blockbuster compounds
Other Rexahn Pharmaceuticals news
-
08/06/10 Rexahn Pharma hires investment banker Frederick Frank as an independent consultant
-
13/05/10 Rexahn Pharma to Initiate Zoraxel Phase IIb trial for treating erectile dysfunction
-
27/04/10 Rick Soni of Rexahn Pharmaceuticals talks about Serdaxin as an anti-depressant, a partnership with Teva Pharmaceuticals and Phase 2 trials.
-
15/04/10 Rexahn Pharmaceuticals to present pre-clinical data for anti-cancer compound at AACR Annual Meeting
-
14/04/10 Rexahn Pharmaceuticals clarifies purpose and results of Serdaxin clinical trial
-
06/04/10 Rexahn Pharmaceuticals submits Phase II study protocol for Serdaxin to US FDA
-
01/04/10 What’s All the Excitement About Rexahn Pharmaceuticals?
-
23/03/10 Rexahn Pharma sets up advisory board to assist with anti-Parkinson’s drug development
Investors interested in Rexahn Pharmaceuticals recently viewed
-
Access Pharmaceuticals (OTCBB: ACCP)
-
Alliance Pharma (AIM: APH)
-
Amphion Innovations (LON: AMP)
-
Asterand (LSE: ATD)
-
Biocompatibles (LSE: BII)
-
BioNeutral Group (OTCBB: BONU)
-
Bionomics (ASX: BNO)
-
Circadian Technologies Limited (ASX: CIR)
-
CogState (ASX: CGS)
-
e-Therapeutics plc (AIM: ETX)
-
Eco Animal Health Group Plc (AIM: EAH)
-
Epistem (AIM: EHP)
-
ImmuPharma PLC (AIM: IMM)
-
Lipoxen (AIM: LPX)
-
Medical Australia Limited (ASX: MLA)
-
Oxford Nutrascience (AIM: ONG)
-
Renovo Group Plc (LSE: RNVO)
-
Silence Therapeutics (AIM: SLN)
-
Starpharma (ASX: SPL)
-
Stirling Products Limited (ASX: STI)
